Internationally Renowned Neurosurgeon and Accomplished Researcher Dr. Linda M. Liau Joins ClearPoint Neuro Board of Directors

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, is pleased to announce that Linda M. Liau, MD, PhD, MBA, has been appointed to the Company’s Board of Directors effective immediately.

Dr. Linda M. Liau is Professor and W. Eugene Stern Chair of the Department of Neurosurgery at the David Geffen School of Medicine at UCLA. She is the Co-Director of the UCLA Brain Tumor Center, and Principal Investigator and Director of the NCI-designated UCLA Brain Tumor SPORE (Specialized Program of Research Excellence). Dr. Liau has authored over 200 peer-reviewed research articles and is internationally recognized for her achievements in understanding the immunology of malignant brain tumors and pioneering the use of dendritic cell-based vaccines for glioblastoma. Clinically, she has developed novel ways to map brain function during awake brain tumor surgeries using functional MRI (fMRI) correlates and specializes in surgery for brain tumors in eloquent areas. Dr. Liau received her BS and BA degrees from Brown University. She earned her MD degree from Stanford University, and a PhD degree in Neuroscience from UCLA. After completing her residency and fellowship training in neurosurgery at UCLA, she joined the faculty at the UCLA School of Medicine. While practicing, she earned an MBA from the UCLA Anderson School of Management.

“We are delighted by the addition of Linda to our Board and by the contributions she will make to our company and strategy, especially given her direct experience in neuro-based biologics and drug delivery,” commented Joe Burnett, President and CEO at ClearPoint Neuro. “Patients are the top priority for everyone at ClearPoint. Adding a practicing neurosurgeon and accomplished researcher to our board will be highly valuable to ClearPoint as we execute our mission to treat and transform the lives of patients suffering from the most debilitating neurological disorders.”

“I am excited to join ClearPoint’s Board and bring my experience as a neurosurgeon to the team, especially as the Company expands into such promising therapeutic areas as gene therapy, stem cell delivery, laser ablation and brain computer interfaces,” stated Dr. Liau.